# Tesamorelin Peptide

> Tesamorelin is a GHRH analog that stimulates pituitary GH release, raises IGF-1 signaling, and reduces excess visceral abdominal fat in HIV lipodystrophy.

Canonical: https://pepflow.app/peptides/tesamorelin/

The VAT Reducer

A growth hormone-releasing hormone analog whose clinical identity centers on excess abdominal fat in HIV-associated lipodystrophy and downstream GH/IGF-1 signaling.

Visceral fat  GH pulse  Body composition

Tier A

Evidence Strong

Safety Well-Studied

FDA status Approved

Last reviewed August 17, 2026 42 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone that stimulates pituitary GH release and downstream IGF-1. It belongs with GHRH analogs rather than ghrelin-receptor GHRPs such as ipamorelin, GHRP-2, or GHRP-6.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

The molecule is built around an upstream endocrine signal: cue the pituitary, raise GH pulsatility, and let downstream IGF-1 and metabolic effects carry the clinical question. That upstream position is why glucose, IGF-1, fluid retention, and growth-signal monitoring matter.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

Product names matter for tesamorelin. EGRIFTA SV and EGRIFTA WR are both tesamorelin products, but they are different formulations with different dose, reconstitution, storage, and administration instructions. The molecule should be understood together with the specific product form.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

## What Tesamorelin is investigated for

Tesamorelin evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Visceral fat reduction in HIV lipodystrophy Injectable 86% Strong

Visceral-fat reduction in HIV-associated lipodystrophy is the highest-confidence tesamorelin use and should stay population-specific.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

#### Human evidence

Randomized trials and labeling support reduced excess abdominal fat in adults with HIV-associated lipodystrophy.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

#### Animal / mechanistic evidence

The GHRH mechanism stimulates GH/IGF-1 signaling, which is tied to the visceral-fat effect and monitoring needs.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

### ### GH-axis stimulation and IGF-1 response Injectable 68% Moderate

The GH/IGF-1 mechanism is strong, but hormone response alone does not establish broad wellness benefit.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

#### Human evidence

Human labeling and trials show GH-axis activity and IGF-1 response, but outcome claims depend on the population studied.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

#### Animal / mechanistic evidence

GHRH receptor agonism explains the GH and IGF-1 response.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

### ### Fat and lean-mass outcomes outside HIV lipodystrophy Injectable 50% Emerging

Outside HIV lipodystrophy, fat and lean-mass claims should stay study-specific and monitored rather than generalized to healthy-aging use.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/23015655/>) [\[23\]](<https://pubmed.ncbi.nlm.nih.gov/31237318/>)

#### Human evidence

Small randomized studies in obese adults with reduced GH secretion and in adults with HIV report fat, lean-mass, or muscle-fat findings, but populations and endpoints differ from general wellness use.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/23015655/>) [\[23\]](<https://pubmed.ncbi.nlm.nih.gov/31237318/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/24178787/>)

#### Animal / mechanistic evidence

GHRH receptor agonism and downstream GH/IGF-1 signaling provide the fat and lean-mass rationale.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

### ### Liver fat and NAFLD Injectable 50% Emerging

Liver-fat claims should stay HIV-associated NAFLD-specific until broader liver endpoint data exist.[\[24\]](<https://pubmed.ncbi.nlm.nih.gov/31611038/>) [\[26\]](<https://pubmed.ncbi.nlm.nih.gov/32270862/>)

#### Human evidence

Randomized HIV-associated NAFLD studies report liver-fat and fibrosis-related signals, but hard liver outcomes and broader populations remain uncertain.[\[17\]](<https://pubmed.ncbi.nlm.nih.gov/25038357/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/31611038/>) [\[26\]](<https://pubmed.ncbi.nlm.nih.gov/32270862/>)

#### Animal / mechanistic evidence

GH-axis and visceral-fat effects provide a plausible metabolic link.[\[17\]](<https://pubmed.ncbi.nlm.nih.gov/25038357/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/31611038/>)

### ### Cognitive function Injectable 38% Preliminary

Cognitive findings are exploratory and should not be presented as cognitive enhancement.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/22869065/>) [\[30\]](<https://pubmed.ncbi.nlm.nih.gov/39813152/>)

#### Human evidence

Small GHRH and tesamorelin studies have evaluated cognitive or neurocognitive endpoints, but findings remain exploratory.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/22869065/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/23689947/>) [\[30\]](<https://pubmed.ncbi.nlm.nih.gov/39813152/>)

#### Animal / mechanistic evidence

GH/GHRH signaling gives a plausible neuroendocrine rationale, but it is not a direct cognitive-enhancement mechanism.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/22869065/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/23689947/>)

## Evidence snapshot

### Overall confidence

Strong

84%

The approved HIV-lipodystrophy visceral-fat indication is backed by randomized trials and labeling. Off-label body-composition, liver-fat, or wellness uses need separate, lower-confidence framing.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

85%

### Human evidence

Strong

Randomized trials and FDA labeling support visceral adipose tissue reduction in HIV-associated lipodystrophy.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18690162/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

65%

### Animal / preclinical

Moderate

Nonclinical pharmacology explains GHRH analog action, while the practical evidence base comes mainly from human trials and labeling.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

82%

### Mechanism support

Strong

GHRH receptor stimulation links tesamorelin to GH release, IGF-1 elevation, and visceral-fat changes in the approved population.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

## Forms & administration

Tesamorelin is tracked with one unbranded vial-and-syringe calculator preset based on the 2 mg once-daily dose used in randomized human trials.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 2 mg per dose.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

### Frequency

Usually taken once daily.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

### Timing Considerations

Evening is the usual timing.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

### Cycle Length

Treatment commonly runs for at least 180 days.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18690162/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

[Full Tesamorelin dosage guide](<https://pepflow.app/peptides/tesamorelin/dosage/>)

## What to expect

### Weeks 4-8

Injectable label-based treatment may first show waist or abdominal-fullness changes while glucose and IGF-1 labs provide context.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

### Weeks 12-26

Visceral-fat and waist trends are most meaningful over the clinical-trial window, where pivotal studies used CT-measured VAT.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

### After stopping

Abdominal-fat benefit can move back toward baseline when treatment stops, so maintenance decisions matter.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18690162/>)

## Safety profile

Tesamorelin has prescription-label safety context for injectable treatment. Practical safety attention belongs on injection-site tolerance, musculoskeletal symptoms, glucose intolerance or diabetes monitoring, IGF-1 elevation, active malignancy, pregnancy, and label-specific contraindications.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

### Common side effects

- Injection-site pain or swelling [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)
- Joint discomfort [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)
- Muscle discomfort [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

### Cautions

- Active malignancy[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)
- Pituitary-axis conditions[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)
- Glucose monitoring[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

### What we don't know

Long-term cardiovascular safety has not been established in labeling.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

## Who Tesamorelin is not for

Route-specific avoid and medical-review notes:

- **Active malignancy**

  Tesamorelin labeling includes active malignancy as a contraindication.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)
- **Pregnancy**

  Tesamorelin is contraindicated in pregnancy because visceral fat reduction offers no benefit and may cause fetal harm.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Documented interactions

- **Diabetes medications**

  Injectable tesamorelin can worsen glucose tolerance, so diabetes therapy and glucose labs may need adjustment during treatment.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

### Theoretical interactions

- **Other GH-axis agents**

  GH, GHRPs, or other GHRH analogs can add overlapping IGF-1 and fluid-retention effects with injectable tesamorelin; this is a stack-level safety caution.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

## Pairing notes

### Not recommended with

**Somatropin: compounded GH/IGF-1 effects** Injectable

Tesamorelin increases the body's own growth-hormone release, while somatropin supplies growth hormone directly. Using both can compound GH/IGF-1, fluid-retention, and glucose effects.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[38\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

**CJC-1295: overlapping GHRH signaling** Injectable

Tesamorelin and CJC-1295 both stimulate GHRH receptors to increase growth-hormone and IGF-1 signaling. Using both duplicates the same upstream GH-axis mechanism without an established combined regimen.[\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[39\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[40\]](<https://www.fda.gov/media/183819/download>)

**Sermorelin: overlapping GHRH signaling** Injectable

Tesamorelin and sermorelin both activate GHRH-receptor signaling and increase endogenous growth-hormone release. Their different formulations do not establish a benefit from overlapping use.[\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[41\]](<https://pubmed.ncbi.nlm.nih.gov/8772599/>) [\[42\]](<https://www.fda.gov/media/94155/download>)

## Regulatory status

### United States

FDA-approved injectable tesamorelin products exist for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approved label does not cover general weight loss, fitness, anti-aging, or unsupervised compounded-use claims.[\[32\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>) [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Approved · FDA-approved injectable tesamorelin products exist for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The label does not cover general weight loss, fitness, or anti-aging use.[\[32\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>) [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[37\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Not Listed · Because FDA-approved injectable tesamorelin products exist, regulatory interpretation should start with the product label. Any compounded version would still be separate from FDA approval for that compounded product.[\[32\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>) [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[37\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |

### Injectable

FDA drug approval

Approved

FDA-approved injectable tesamorelin products exist for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The label does not cover general weight loss, fitness, or anti-aging use.[\[32\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>) [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[37\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Not Listed

Because FDA-approved injectable tesamorelin products exist, regulatory interpretation should start with the product label. Any compounded version would still be separate from FDA approval for that compounded product.[\[32\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>) [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>) [\[37\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### International

EU/Europe, UK, Canada, and Australia access depends on local brand authorization, indication, and prescribing pathway; the U.S. EGRIFTA label should not be generalized to every market.

### Sports & competition

WADA's 2026 Prohibited List treats tesamorelin/GHRF analog use as prohibited under S2; tested athletes should treat injectable use as prohibited without a valid TUE.[\[38\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

Tesamorelin is a GHRH analog that stimulates pituitary GHRH receptors, increasing pulsatile growth hormone release and downstream IGF-1. In its approved context, that GH-axis signal is tied to reduced excess abdominal visceral fat in adults with HIV-associated lipodystrophy.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

The same pathway explains the label cautions: IGF-1 can rise, glucose tolerance can change, fluid-retention symptoms can occur, and neoplasm history matters. Subcutaneous delivery and the labeled population are part of the mechanism interpretation; it should not be generalized to ordinary weight loss or anti-aging.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

## Research gaps & open questions

What the current literature has not yet settled about Tesamorelin:

01

Long-term cardiovascular safety remains unclear beyond the available label and extension data, including risks such as heart attack or stroke.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

02

Each off-label use—general fat loss, fatty liver disease, cognition, or nerve injury—needs its own trials; evidence from HIV-related abdominal fat cannot establish those benefits.[\[26\]](<https://pubmed.ncbi.nlm.nih.gov/32270862/>) [\[36\]](<https://clinicaltrials.gov/study/NCT03150511>)

03

Direct comparisons with current obesity and metabolic medicines are scarce, so relative weight loss, side effects, and long-term benefit cannot be inferred.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)

## Common questions

### What is tesamorelin approved for?

Tesamorelin is approved as an injectable drug to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

### Is tesamorelin a general weight-loss drug?

No. It is not for weight-loss management; the strongest evidence is for adults with HIV-associated lipodystrophy.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

### Is tesamorelin allowed in tested sports?

No. WADA prohibits tesamorelin and other growth hormone releasing factors under S2 unless a valid anti-doping pathway applies.[\[38\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Myths & misconceptions

### Myth

FDA-approved for visceral fat means tesamorelin is approved for anyone who wants fat loss.

### Reality

The approval is specific to excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

### Myth

EGRIFTA WR and EGRIFTA SV can be substituted milligram for milligram.

### Reality

The labels state the formulations have different dosing, reconstitution, storage, and administration instructions and are not substitutable.[\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

## History & discovery

Tesamorelin's history is different from many peptide-library entries because it moved from GHRH analog pharmacology into an FDA-approved, narrowly labeled HIV-lipodystrophy drug.[\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>)

Randomized trials tested whether a growth-hormone-releasing factor analog could reduce visceral adipose tissue in adults with HIV-associated abdominal fat accumulation.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18057338/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)

The approval history made tesamorelin a regulated prescription product for one specific use, not a general weight-loss or anti-aging peptide.[\[32\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>) [\[33\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)

EGRIFTA WR labeling continued the same HIV-lipodystrophy indication while later research explored liver fat and other HIV-associated metabolic questions.[\[34\]](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)

## Published research 42 citations

- [\[1\] **Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.** Current opinion in investigational drugs (London, England : 2000), 2006 Oct. review.](<https://pubmed.ncbi.nlm.nih.gov/17086939/>)
- [\[2\] **Metabolic effects of a growth hormone-releasing factor in patients with HIV.** The New England journal of medicine, 2007 Dec 6. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/18057338/>)
- [\[3\] **Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.** AIDS (London, England), 2008 Sep 12. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/18690162/>)
- [\[4\] **Tesamorelin, a human growth hormone releasing factor analogue.** Expert opinion on investigational drugs, 2009 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/19243281/>)
- [\[5\] **Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.** Journal of acquired immune deficiency syndromes (1999), 2010 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/20101189/>)
- [\[6\] **Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.** AIDS (London, England), 2011 Jun 19. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/21516030/>)
- [\[7\] **Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.** Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2011 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/21531600/>)
- [\[8\] **Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.** Drugs, 2011 May 28. review.](<https://pubmed.ncbi.nlm.nih.gov/21668043/>)
- [\[9\] **Spotlight on tesamorelin in HIV-associated lipodystrophy.** BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011 Dec 1. review.](<https://pubmed.ncbi.nlm.nih.gov/22050344/>)
- [\[10\] **Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.** HIV/AIDS (Auckland, N.Z.), 2011. review.](<https://pubmed.ncbi.nlm.nih.gov/22096409/>)
- [\[11\] **Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.** The Annals of pharmacotherapy, 2012 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/22298602/>)
- [\[12\] **Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/22495074/>)
- [\[13\] **Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.** Archives of neurology, 2012 Nov. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/22869065/>)
- [\[14\] **Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.** The Journal of clinical endocrinology and metabolism, 2012 Dec. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/23015655/>)
- [\[15\] **Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.** JAMA neurology, 2013 Jul. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/23689947/>)
- [\[16\] **The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.** The Journal of clinical endocrinology and metabolism, 2014 Jan. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/24178787/>)
- [\[17\] **Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.** JAMA, 2014 Jul 23-30. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25038357/>)
- [\[18\] **Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.** Clinical pharmacokinetics, 2015 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25358450/>)
- [\[19\] **Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.** Journal of pharmacokinetics and pharmacodynamics, 2015 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25895899/>)
- [\[20\] **Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.** PloS one, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26457580/>)
- [\[21\] **Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.** PloS one, 2017. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/28617838/>)
- [\[22\] **Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.** Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2017 Dec. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/29031905/>)
- [\[23\] **The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.** The Journal of frailty & aging, 2019. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/31237318/>)
- [\[24\] **Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.** The lancet. HIV, 2019 Dec. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/31611038/>)
- [\[25\] **Tesamorelin.** PubMed, 2012. review.](<https://pubmed.ncbi.nlm.nih.gov/31644039/>)
- [\[26\] **Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021 Jun 15. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/32270862/>)
- [\[27\] **Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.** JCI insight, 2020 Aug 20. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/32701508/>)
- [\[28\] **Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021 Aug 16. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33852720/>)
- [\[29\] **Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.** AIDS (London, England), 2024 Oct 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38905488/>)
- [\[30\] **Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.** The Journal of infectious diseases, 2025 Jun 2. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39813152/>)
- [\[31\] **Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.** Obesity research & clinical practice, 2026 Jan-Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/41545261/>)
- [\[32\] **Drugs@FDA/openFDA query for tesamorelin approved products** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22TESAMORELIN%22&limit=1>)
- [\[33\] **EGRIFTA SV- tesamorelin kit** DailyMed / National Library of Medicine. official guidance.](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224>)
- [\[34\] **EGRIFTA WR- tesamorelin kit** DailyMed / National Library of Medicine. official guidance.](<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>)
- [\[35\] **TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT00608023>)
- [\[36\] **Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT03150511>)
- [\[37\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[38\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[39\] **Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.** PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)
- [\[40\] **FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting** U.S. Food and Drug Administration, 2024. regulatory.](<https://www.fda.gov/media/183819/download>)
- [\[41\] **Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.** The Journal of clinical endocrinology and metabolism, 1996 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8772599/>)
- [\[42\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/media/94155/download>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

A

**Evidence**

84% Strong

**Safety**

Well-Studied

**FDA status**

Approved

**Injectable 503A**

Not Listed

**Citations**

[42 citations](<https://pepflow.app/peptides/tesamorelin/#published-research>)

**Updated**

August 17, 2026

### Potential benefits

- Visceral fat reduction in HIV lipodystrophy
- GH-axis stimulation and IGF-1 response
- Fat and lean-mass outcomes outside HIV lipodystrophy
- Liver fat and NAFLD
- Cognitive function

### Common side effects

- Injection-site pain or swelling
- Joint discomfort
- Muscle discomfort

### Also known as

- Egrifta
- Egrifta SV
- Egrifta WR
- TH9507

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Tesamorelin dosage guide](<https://pepflow.app/peptides/tesamorelin/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
